Can UCB's Bimekizumab Go From Last To First In Psoriasis?

Skin Clearance Data Tops Rivals

 
• By Kevin Grogan
Racing
UCB hopes bimekizumab can overtake Cosentyx for psoriasis • Source: Shutterstock

More from Immunological

More from Therapeutic Category